Cytodyn Inc (CYDY)

[Bill_ENG]

Not a flop. Remember this was a Phase 2 trial, in which a lot of learning happens.

At Day 3 there was a marked difference between the Leronlimab and the control group. By day 14 the Leronlimab and control must not have been different enough. The control got better just as the Leronlimab got better.

Not a flop as Leronlimab group got better sooner.

NEWS2 scores which a a predictor of progression to severe were much better in the Leronlimab arm, once again not a flop.

If 67% of people in the US had not progressed from Moderate to severe we would have had a lot less deaths in the US due to Covid.

This is where the FDA deferred to Big Pharma. They told CYDY to proceed with Phase 3 S/C trial and would not recommend Leronlimab for Mild to Moderate patients because they would get better on their own. Then within a short time frame were recommending Remdesivir and we all know how well that worked.

It works much like Saline.

So the progressions continued in many, and many died as they progressed to Severe and then to critical and then to death.

Yeah, if I was that committee that made that decision, I would really want some time to figure out how to spin those decisions to the powers that be, and the public, and want Cytodyn quiet as church mice while I figure it out.